دورية أكاديمية
Anti-Tumor Potential of a 5-HT3 Receptor Antagonist as a Novel Autophagy Inducer in Lung Cancer: A Retrospective Clinical Study with In Vitro Confirmation
| العنوان: | Anti-Tumor Potential of a 5-HT3 Receptor Antagonist as a Novel Autophagy Inducer in Lung Cancer: A Retrospective Clinical Study with In Vitro Confirmation |
|---|---|
| المساهمون: | Jeong Soo Lee, Seong Yong Park, Na Young Kim, Dong Wook Kim, Ju Eun Oh, Eunjin Heo, Jong Seok Lee, Young Chul Yoo, Kim, Na Young |
| بيانات النشر: | MDPI AG |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | lung neoplasm, palonosetron, ramosetron, serotonin antagonist |
| الوصف: | Unlike 5-hydroxytryptamine (5-HT, serotonin) 1 and 5-HT2, the effect of 5-HT3 receptors on tumor cells is poorly understood. We conducted this study to determine whether the perioperative use of 5-HT3 receptor antagonists, which are widely used antiemetics, impacts the recurrence and mortality after lung cancer surgery and related anti-tumor mechanisms. From data on 411 patients, propensity score matching was used to produce 60 1:2 matched pairs of patients, and variables associated with the prognosis after open lung cancer surgery were analyzed. Additionally, the effects of 5-HT3 receptor antagonists were confirmed in vitro on A549 human lung adenocarcinoma cells. Cancer recurrence occurred in 10 (8.2%) and 14 (22.95%) patients (p = 0.005), treated or untreated, with palonosetron or ramosetron. Perioperative usage of palonosetron or ramosetron was also associated with lower recurrence rate after lung cancer surgery (hazard ratio (HR), 0.293; 95% confidence interval (CI) 0.110-0.780, p = 0.0141). Our in vitro experiments also showed that palonosetron and ramosetron inhibited cell proliferation and colony formation and reduced migration, which was associated with autophagic cell death via the extracellular signal-regulated kinase (ERK) pathway. Palonosetron and ramosetron may have anti-tumor potential against lung cancer cells, suggesting the need to consider these drugs as first-choice antiemetics in patients undergoing lung cancer surgery. ; open |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 2077-0383 |
| العلاقة: | Journal of Clinical Medicine; J03556; OAK-2019-04387; https://ir.ymlib.yonsei.ac.kr/handle/22282913/171406Test; T201903479; Journal of Clinical Medicine, Vol.8(9) : E1380, 2019; 63282 |
| DOI: | 10.3390/jcm8091380 |
| الإتاحة: | https://doi.org/10.3390/jcm8091380Test https://ir.ymlib.yonsei.ac.kr/handle/22282913/171406Test |
| حقوق: | CC BY-NC-ND 2.0 KR |
| رقم الانضمام: | edsbas.1C639BB4 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 20770383 |
|---|---|
| DOI: | 10.3390/jcm8091380 |